Rockville, Nov. 05, 2023 (GLOBE NEWSWIRE) -- As per Fact.MR, a provider of market research and competitive intelligence, the global atherosclerosis drugs market is likely to arrive at a value of US $62.8 Bn by the end of 2033 while growing at a CAGR of 2.3%.
Atherosclerosis drugs are medicines designed to treat the buildup of fatty deposits in arteries, a condition known as atherosclerosis. These drugs work by targeting the underlying processes that lead to plaque formation, helping to improve blood flow and reduce the risk of heart attacks and strokes. In fact, these drugs are backed by strong scientific evidence and can be used alongside lifestyle changes like a healthy diet and exercise. They offer a tailored approach to treatment based on individual patient characteristics, and in some cases, can help avoid the need for invasive procedures.
Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4434
Market growth is primarily driven by the escalating global prevalence of cardiovascular diseases & obesity, which includes atherosclerosis-related conditions like coronary artery disease and stroke. Moreover, as unhealthy lifestyle habits persist, the incidence of atherosclerosis continues to rise, fueling the demand for effective pharmaceutical interventions.
However, developing effective drugs for atherosclerosis, a complex artery-clogging condition, is a tough and lengthy process. It involves understanding intricate biological processes and conducting rigorous clinical trials to ensure safety and effectiveness.
| Report Attribute | Details |
| Value Projection (2033) | US$ 62.8 Billion |
| Growth Rate (2023-2033) | 2.3% CAGR |
| No. of pages | 170 Pages |
| No. of Tables | 20 Tables |
| No. of Figures | 99 Figures |
Key Takeaways:
- As per region, Asia Pacific is expected to emerge as a highly opportunistic market during the forecast period. In fact, India, China, and Japan are estimated to be the lucrative markets in the region. This growth is driven by various factors such as the increasing geriatric population and rising investments in healthcare infrastructure development.
- Also, the United States is expected to hold a substantial share during the forecast period due to the growing prevalence of cardiovascular disorders and high incidence of obesity.
- As per the drug class, cholesterol-lowering medication sales are expected to soar during the forecast period due rise in the adoption of sedentary lifestyles and limited physical ability.
The increasing prevalence of cardiovascular diseases, advancements in drug development, and rising awareness about atherosclerosis prevention and treatment are the key factors driving the market growth - Says FACTMR Expert
Key Companies Profiled in This Report
- Merck & Co. Inc.
- Sanofi
- Hoffmann La-Roche Ltd.
- Bayer AG
- Pfizer Inc.
- Novartis AG
- GlaxoSmithKline Plc
- Janssen Global Services LLC
- Amgen Inc.
- Mylan N.V.
Market Competition
In the fiercely competitive atherosclerosis drug market, major suppliers are prioritizing the introduction of generic drugs to capitalize on sales opportunities and address the growing demand in the Asia Pacific region.
- In August 2022, Cadila Pharmaceuticals, an Indian pharmaceutical company, revealed the introduction of generic versions of sitagliptin. Sitagliptin belongs to the drug class of DPP-4 inhibitors and is employed in the management of hyperglycemia, a condition associated with complications such as heart attacks, strokes, and atherosclerosis.
Winning strategies
- Key companies should focus on innovation such as focusing on the development of innovative lipid-lowering drugs is an effective strategy for success in the Atherosclerosis Drugs Market. PCSK9 inhibitors represent a newer class of drugs that target a protein involved in cholesterol regulation.
- Moreover, leading companies in the business should focus on creating advanced drug delivery systems such as injectables or implantable devices. These innovations can make it easier and more convenient for patients to manage atherosclerosis.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=4434
Country-wise Insights
Which nation is claiming to be the dominant one in North America?
"Substantial Revenue Share to Be Held by the United States"
Due to the high incidence of obesity and the rising prevalence of cardiovascular illnesses, the United States is expected to account for a large portion of the global market for atherosclerosis drug shipments during the forecast period. Other factors that are projected to support market expansion in the nation throughout the forecast period include ageing populations, sedentary lifestyles, poor eating habits, and the expanding availability of medications to treat atherosclerosis.
According to data from the Centres for Disease Control and Prevention (CDC) website, around 805,000 Americans get a heart attack year and one person dies in the US from cardiovascular disease every 34 seconds.
Future atherosclerosis medication sales in the US may benefit from supportive programmes to advance medical research as well as the introduction of advantageous insurance and reimbursement regulations. Future prospects for the nation's producers of atherosclerosis medications are expected to be enhanced by rising public knowledge of the condition and the advent of innovative therapies.
Explore More Related Studies Published by Fact.MR Research:
Platelet Aggregation Devices Market: The global platelet aggregation devices market is estimated to reach US$ 1.05 billion by 2027.
Anti-Platelet Agents Market: Global demand for anti-platelet agents is projected to reach a market valuation of US$ 4.8 billion by the end of 2033.
Platelet-Rich Plasma Market: Platelet-rich plasma uptake is poised to surge at a staggering 12% CAGR to surpass US$ 1.5 Bn by 2031.
About Fact.MR:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
